Kornimate/medical-research-clean huggingface dataset:
artificial intelligence confocal laser endomicroscopy for real-time assessment of gastric cancer risk.

Conditions: Intestinal Metaplasia of Gastric Mucosa; Confocal Laser Endomicroscopy

Summary: current national guidelines recommend the use of olgim score to evaluate the risk of gastric cancer in patients, and close gastroscopic monitoring should be performed after olgim grade iii/iv. however, it would not be clinically feasible to require at least four biopsies. confocal laser endomicroscopy is able to magnify the tissue by 1000x, which can be seen at the cellular level. observing goblet cells under confocal laser endomicroscopy is simpler and diagnostic accuracy is comparable to pathology. confocal laser endomicroscopy enables better assessment of intestinal metaplasia in gastric mucosa, thus quantifying the risk of gastric cancer and avoiding multiple biopsies.

globally, gastric cancer is the fifth most prevalent malignancy and the third leading cause of cancer mortality. current national guidelines recommend the use of olgim score to evaluate the risk of gastric cancer in patients, and close gastroscopic monitoring should be performed after olgim grade iii/iv. however, it would not be clinically feasible to require at least four biopsies. confocal laser endomicroscopy is able to magnify the tissue by 1000x, which can be seen at the cellular level. observing goblet cells under confocal laser endomicroscopy is simpler and diagnostic accuracy is comparable to pathology. confocal laser endomicroscopy enables better assessment of intestinal metaplasia in gastric mucosa, thus quantifying the risk of gastric cancer and avoiding multiple biopsies. the investigators aim to design the cggim scores to evaluate gastric cancer risk.

Eligibility criteria:
inclusion criteria: * patients aged 40-80 years undergoing the confocal laser endomicroscopy examination exclusion criteria: * patients with severe cardiac, cerebral, pulmonary or renal dysfunction or psychiatric disorders who cannot participate in gastroscopy * patients with previous surgical procedures on the stomach * patients with contraindications to biopsy * patients who refuse to sign the informed consent form
assessing the clinical utility of tacs

Conditions: Anxiety Disorders and Symptoms; Sensory Disorders; Hypervigilance; Post Traumatic Stress Disorder

Summary: the present study seeks to evaluate the clinical utility of repeated transcranial alternating current stimulation (tacs) by assessing long-term, lasting changes in oscillatory activity and subsequent changes in related behavioral processes of anxious arousal and sensory sensitivity. to date, only transient effects of tacs have been reported, lasting no longer than 30 to 70 minutes. in order to be truly impactful within a clinical setting, however, evidence for long-term effects of tacs is needed.

recent years have witnessed increasing recognition of "oscillopathies", neuropsychiatric disorders characterized by aberrations in the neural oscillations that orchestrate various mental activities. transcranial alternating current stimulation (tacs) provides an effective way to directly modulate these oscillations in a non-invasive and frequency-specific manner, offering groundbreaking insights into the workings of the brain and, importantly, the development of novel treatments for these oscillopathies. however, evidence is lacking for the ability of tacs to induce long-term neural plasticity and lasting behavioral changes, which is critical for establishing the clinical utility of this novel intervention. here, we are administering 30 minutes of alpha-frequency tacs over occipitoparietal sites for four consecutive days to evaluate both transient and long-term changes in alpha oscillatory power and long-range, directed oscillatory connectivity. as both anxious arousal and sensory sensitivity are highly related to alpha oscillations, as well as numerous neuropsychiatric disorders, changes in these behavioral outcomes were subsequently evaluated to assess clinically-relevant outcomes of the repeated tacs protocol.

Eligibility criteria:
inclusion criteria: * right-handed exclusion criteria: * history of severe neurological disorder or traumatic brain injury * psychotropic medication use * metal plates/implants in head * pregnancy * implanted medical devices (e.x. pacemaker)

Keywords: oscillations non-invasive brain stimulation transcranial alternating current stimulation
cardiac changes in myeloproliferative neoplasms

Conditions: Myeloproliferative Neoplasm

Summary: myeloproliferative neoplasms are heterogeneous group of clonal hematopoietic stem cell neoplasms with excessive proliferation of one or more of the erythroid, megakaryocytic, or myeloid lineages and relatively normal maturation resulting in increased numbers of red cells, platelets, and/or granulocytes in the peripheral blood. constitutive tyrosine kinase activation appears to be a common pathogenetic mechanism.

according to worldwide study of prevalence of myeloproliferative neoplasms revealed: incidence of polycythemia vera ranged 0.01 to 2.61 per 100.000 population and the prevalence ranging from 0.49 to 46.88 per 100.000 population. incidence of essential thrombocythemia is 0.21 to 2.27 per 100.000 population, prevalence ranging between 11.00 - 42.51 per 100.000 population. primary myelofibrosis incidence is 1.15 -4.99 per 100.000 population and prevalence ranging between 1.76 - 4.05 per 100.000 population.in previous studies, cardiac involvement including coronary arterial thrombosis, myocardial infarction, pulmonary hypertension, asymptomatic pericardial effusion, cardiac tamponade, intractable cardiac failure due to intraventricular stenosis and valvular stenosis that occur in myeloproliferative neoplasms. there is a few number of studies in which cardiac lesions were evaluated in myeloproliferative neoplasms by using transthoracic echocardiography but still inadequate, so we need to understand more about cardiovascular complications in myeloproliferative neoplasms.

Eligibility criteria:
inclusion criteria: * diagnostic criteria of myeloproliferative neoplasms. exclusion criteria: * extreme body weight e.g., morbid obesity. * cardiac disease. * cerebrovascular disorders. * diabetes mellitus. * dyslipidemia.
investigating integrative therapies for symptom management in adults with acute leukemia

Conditions: Acute Myeloid Leukemia

Summary: this pilot study will use a mixed methods approach to evaluate the feasibility and acceptability of integrative therapies, a bedside service offering mindfulness-based interventions (still meditation, meditative movement, relaxation techniques, and massage therapy) as non-pharmacologic treatment for symptom management in newly diagnosed adult acute myeloid leukemia (aml) patients undergoing induction chemotherapy

uf health integrative therapies inpatient program offers mindfulness-based interventions consisting of still meditation, meditative movement, relaxation techniques, and massage therapy to patients at the bedside. this mixed methods feasibility pilot aims to move toward optimal use of the integrative therapies service amongst aml patients undergoing induction chemotherapy by: 1) examining the feasibility and acceptability of this intervention and describing the distribution of variables, 2) developing a greater understanding of patient experience, and 3) exploring facilitators and barriers to engagement with the service. the investigators intend to use the data collected from this study to inform a subsequent multi-site study with a larger sample size and adjustments depending on the results from this investigation. the study team will also explore the acceptability to participation in integrative therapies bedside service by conducting a qualitative, phenomenological thematic analysis of patient interviews. the intent of a convergent design is to merge the analyses of the quantitative and qualitative data that are gathered during the implementation of integrative therapies bedside service.

Eligibility criteria:
inclusion criteria: * admitted to local area bone marrow transplant unit or hematology/oncology during the study period * diagnosed with acute leukemia * receiving high-grade mds induction chemotherapy * within first 3 days of chemotherapy initiation * age \> 18 years * able to speak/read english exclusion criteria: -altered mental status or diminished level of consciousness as established by daily progress note documented by health care provider, nursing assessment, or at the discretion of the integrative therapies practitioner
visual acuity after the combined binocular implantation of +2.0 diopters and +3.0 diopters oculentis multifocal intraocular lenses.

Conditions: Cataract

Summary: the objective of this study is to assess the visual outcome after the combined binocular implantation of +2.0 d and +3.0 d refractive multifocal intraocular lenses.

bifocal multifocal intraocular lenses (miol) are effective in achieving good uncorrected visual acuities in the distance and the near. however, the intermediate vision is of increasing relevance for everyday's life. several multifocal intraocular lenses have been developed to improvement intermediate vision. nonetheless, those systems still possess adverse photic effects and do not garantuee spectacle independence. therefore, the combination of a lower-addition bifocal intraocular lense in the distance-dominant eye with a higher-addition bifocal intraocular lense in the fellow-eye might be a promising approach to address these drawbacks of current binocular and trifocal intraocular lenses.

Eligibility criteria:
inclusion criteria: * clinically significant cataract * endothelial cell count: patients aged 18-75 years: \> 1000 cells/mm2; patients \> 75 years: \> 750 cells/mm2 * absence of vision-limiting corneal or retinal comorbidities * capability to understand the informed consent exclusion criteria: * expected postoperative astigmatism \> 0.75 diopters * irregular astigmatism * dilated pupil diameter \< 3 mm * corneal and fundus abnormalities that might cause visual impairments * inability to attend follow-up visits

Keywords: multifocal intraocular lens binocular trifocality cataract surgery spectacle independence intermediate vision photopic vision mesopic vision scotopic vision binocular vision
evaluating the effectiveness of telemonitoring system in the management of patients with cidp

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy

Summary: chronic inflammatory demyelinating polyneuropathy (cidp) is a chronic demyelinating polyneuropathy of autoimmune origin with a progressive or relapsing course. diagnosis is based on clinical presentation and electrophysiological findings in accordance with the efns/pns consensus guidelines. ivig is the first line treatment witch has been shown to be effective in several placebo-controlled trials. once ivig therapy produces a response and is well tolerated, some patients are able to continue their treatment in the home setting. the home link system offers an integrated, global solution based on telemonitoring technology providing continuous, remote monitoring of privigen® infusions administered at home.


Eligibility criteria:
inclusion criteria: * patient with a diagnosis of cidp as per efns/pns criteria. * patient already receiving home-based treatment with privigen® exclusion criteria: * not applicable

Keywords: cidp telemonitoring telemedicine
perfusion index variability in respiratory distress syndrome

Conditions: Poor Peripheral Perfusion

Summary: perfusion index may vary according to type of surfactant during the treatment of respiratory distress syndrome.

peripheral tissues of preterm infants are very sensitive for hypoperfusion, but there are rare data in the literature for peripheral perfusion after surfactant treatment. in this study the investigators aimed to compare the perfusion index (pi) variability in premature infants with respiratory distress (rds) following instillation of one of two different natural surfactant preparations.

Eligibility criteria:
inclusion criteria: * premature infants \< 32 weeks of gestational age exclusion criteria: * congenital malformation * apgar scores \<3 at 5 min

Keywords: natural surfactants; perfusion index
the six-minute walking test (6mwt) as a measure of functional impairment in lumbar degenerate disc disease.

Conditions: Lumbar Disc Disease; Lumbar Spine Degeneration; Lumbar Spinal Stenosis

Summary: the study determines the reliability and validity of the 6-minute walking test (6mwt) in patients with lumbar degenerative disc disease (ddd).

the purposes of the study is to assess the ability of the 6-minute walking test (6mwt) as a reliable and standardized objective outcome assessment and its relation to already established subjective patient reported outcome measures in patients suffering from lumbar degenerative disc disease. we want to use an existing smartphone-application that uses global positioning system (gps) coordinates to measure walking distance. applying self- measurement of the 6mwt before and after a therapeutic intervention, we determine objective functional impairment (ofi) in patients. the results of this study add to the understanding of achievable objective outcomes after therapeutic interventions applied to patients with ddd and examines patients acceptance for smartphone based self-measurement. primary objectives the primary objective is to determine the reliability and validity of the 6-minute walking test (6mwt) in patients with lumbar degenerative disc disease (ddd) secondary objectives are 1. to correlate objective functional impairment (ofi) with already established patient-rated outcome measures (proms) in the sense of cross-validation. 2. to correlate ofi, as determined by the 6mwt with ofi that is determined by another objective test, the tug test 3. to then analyze the change in ofi in patients before and after surgical intervention 4. to determine whether patients prefer the objective (6mwt) or subjective (proms) repeated assessment of their functional condition.

Eligibility criteria:
inclusion criteria: * patient scheduled for spine surgery with one of the following diagnosis (1) lumbar disc herniation (ldh), (2) lumbar spinal stenosis lumbar (lss) or lumbar ddd with or without instability requiring lumbar fusion (transforaminal lumbar interbody fusion, posterior lumbar interbody fusion, or extreme lateral interbody fusion) * male and female subjects ≥ 18 years * written informed consent exclusion criteria: * pregnancy * inability to walk (extreme pain or severe neurological deficits) * severe chronic obstructive lung disease (copd) corresponding to ≥ gold iii * severe heart failure corresponding to ≥ new york heart association (nyha) iii * lung cancer and diffuse parenchymal lung disease * other medical reasons interfering with the patient's ability to walk and perform the 6mwt (e.g., osteoarthritis disease of the lower extremities, parkinson's disease, heart failure, hip or knee prosthesis etc.) * unavailability for follow up and/or inability to complete assessment (planning to move, no smartphone, etc.).
evaluation of the impact of lock down and end of lock down on the management of patients with inflammatory and dysimmune diseases followed in the context of imminent fhu and covid-19

Conditions: Inflammatory Disease; Covid19

Summary: this questionnaire is distributed via a mailing list (e-mail) of patients treated within the framework of the fhu for pathologies including chronic inflammatory bowel diseases or ibd (crohn's disease and ulcerative colitis), inflammatory rheumatic diseases (such as rheumatoid arthritis and ankylosing spondylitis), but also asthma, psoriasis, atopic dermatitis as well as systemic autoimmune (such as scleroderma, lupus, angioedema) and neurological (multiple sclerosis) diseases. a two-step analysis will be conducted: impact of lock down(march 17, 2020 - may 11, 2020) and a 2-month assessment of end of lock down (from may 11, 2020) on issues addressing: overall impact, impact on the disease, treatment and follow-up, and access to information related to the epidemic during these periods.


Eligibility criteria:
inclusion criteria: patient followed for : * chronic inflammatory bowel disease or ibd (crohn's disease and ulcerative colitis), * inflammatory rheumatism (rheumatoid arthritis and spondylitis) * multiple sclerosis * asthma * psoriasis * atopic dermatitis * systemic autoimmune diseases (scleroderma and lupus) exclusion criteria: * minor patient * patient cannot read or write * patient without computer equipment * patient with no internet access * patient not having filled in his e-mail in his file * patient does not wish to be contacted by email
examining the relationship between ongoing alcohol use, suicidal thoughts and behaviors and related constructs, and behavioral economic decision-making

Conditions: Alcohol Use; Suicidal Ideation/Behavior

Summary: the purpose of this single groups trial is to (aim 1) determine relationships between alcohol use, suicidal thoughts and behaviors (stbs), and behavioral economic decision-making in a community sample (n = 100) of alcohol using adults who are 18 years of age or older, (aim 2) is to determine factors that predict engagement with a remote intervention (computer based training for cognitive behavioral therapy; cbt4cbt) for alcohol and its effects on alcohol use, stbs, and decision-making with those same adults. participants will complete a baseline assessment and be given access for remote, self-guided cbt4cbt modules for alcohol use. following this, participants will remotely complete three follow-up assessments over three months. this will allow for determination of incidence and predictors of alcohol use and stbs and determination of predictors of engagement and efficacy of a remote intervention for alcohol use in both samples.


Eligibility criteria:
inclusion criteria: * at least 18 years old * consume alcohol at least weekly * a score of 8 or greater on the alcohol use disorder identification test (audit) * some interest in cutting back on drinking or quitting * read and understand english exclusion criteria: * a score of 31 or greater on the alcohol use disorder identification test (audit) at baseline * reporting schizophrenia and/or other psychiatric diagnoses other than depression or anxiety at baseline * already being in treatment for alcohol use disorder at baseline * past month substance use other than cannabis or tobacco

Keywords: alcohol cognitive behavioral therapy suicide remote self-guided therapy cbt4cbt
hip abductor strengths, limping and trochanteric tenderness after hip arthroplasty due to femoral neck fracture

Conditions: Femoral Neck Fracture; Trochanteric Pain

Summary: a prospective cohort study to compare the direct lateral and poster-lateral approach concerning abductor function. patients admitted with a femoral neck fracture operated with a hemiarthroplasty through a direct lateral or a poster-lateral approach were screened for inclusion. patients with altered mental status spmsq \>7, pathological fractures, non-walkers were excluded. those who fulfilled the inclusion criteria and non of the exclusion criteria were followed 1 year postoperatively by clinical examination. sample size were estimated to 30 patient in each group. primary outcome variables were trendelenburg test, abductor strength measured with dynamometry, trochanteric tenderness measured with algometry and palptation.


Eligibility criteria:
inclusion criteria: * displaced femoral neck fracture * walker * hemarthroplasty * preiffer test \>7/10 exclusion criteria: * pathological fracture * non-walker * pfeiffer test \<7/10 indicating mental alteration.

Keywords: femoral neck fracture,surgical approach, limp, abductor strenght, trochanteric pain
a safety and tolerability evaluation of two 10-week dose regimens of orally-administered pf-04494700 in alzheimer's patients

Conditions: Alzheimer Disease

Summary: a 10-week safety and tolerability study of a potential treatment for mild to moderate alzheimer's disease.


Eligibility criteria:
inclusion criteria: * diagnosis of probably alzheimer's disease for at least 1 year. * mini mental state exam (mmse) score between 12-26 at screening. * participants must be receiving a cholinesterase inhibitor and/or memantine for at least 4 months, and on a stable dose for at least 2 months. exclusion criteria: * current evidence of a neurological or psychiatric illness that could contribute to dementia. * living alone. * poorly controlled high blood pressure.

Keywords: interventional, alzheimer, safety and tolerability
compression therapy versus surgery in the treatment of superficial venous reflux

Conditions: Venous Insufficiency

Summary: randomized controlled trial, a method used to implement the random allocation sequence is numbered containers. the aim of the study is to compare compression therapy with compression stockings and surgery eliminating superficial venous reflux in patients with duplex ultrasound verified superficial venous reflux without skin changes or ulceration.

superficial venous reflux is common in adult population. uncomplicated disease, where there is no skin changes but varicose veins with or without leg swelling, can be totally asymptomatic but also cause various symptoms as pain, aching and discomfort of leg usually caused by increased venous pressure. varicose veins may also cause cosmetic problem. compression stockings relief the symptoms as they normalize venous pressure. in surgical treatment, axial reflux is treated usually by removing incompetent superficial veins. the aim of the study is to compare conservative treatment with compression stockings with surgical treatment of superficial venous reflux. in operative treatment the great saphenous vein or lesser saphenous vein are removed after flush ligation by femoral vein and stripping of the trunk. if the main trunk has been removes previously, axial refluating veins are removed or ligated according to the dus finding. the patients in both groups are examined at the baseline and followed up to two years by ultrasound scanning. patients clinical classification, venous disability score, venous disease severity score, anatomical path of reflux as well as quality of life are studied at the baseline, at one year follow-up and two years follow-up.

Eligibility criteria:
inclusion criteria: * patients with chronic superficial vein insufficiency * patient must be 20-70 years old * degree of difficulty of vein insufficiency c2-c3 * venous disability score 1-2 * patient is agreeable to the study exclusion criteria: * peripheral atherosclerotic occlusive disease * lymphoedema * severe concomitant disease (asa 3-5) * venous ulcers or unclassified skin changes * bmi more than 35

Keywords: venous surgery compression therapy